Xylo Technologies (NASDAQ:XYLO) & GoodRx (NASDAQ:GDRX) Critical Review

Xylo Technologies (NASDAQ:XYLO) and GoodRx (NASDAQ:GDRX) are both small-cap business services companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, institutional ownership, valuation, analyst recommendations and risk.

Valuation and Earnings

This table compares Xylo Technologies and GoodRx”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xylo Technologies	$57.64 million	0.07	-$16.02 million	N/A	N/A
GoodRx	$792.32 million	2.26	-$8.87 million	$0.05	93.20

GoodRx has higher revenue and earnings than Xylo Technologies.

Profitability

This table compares Xylo Technologies and GoodRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Xylo Technologies	N/A	N/A	N/A
GoodRx	-2.05%	5.35%	2.51%

Insider & Institutional Ownership

0.3% of Xylo Technologies shares are owned by institutional investors. Comparatively, 63.8% of GoodRx shares are owned by institutional investors. 2.2% of Xylo Technologies shares are owned by company insiders. Comparatively, 4.2% of GoodRx shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Volatility & Risk

Xylo Technologies has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, GoodRx has a beta of 1.25, suggesting that its stock price is 25% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Xylo Technologies and GoodRx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xylo Technologies	0	0	0	0	0.00
GoodRx	0	3	6	1	2.80

GoodRx has a consensus target price of $8.18, suggesting a potential upside of 75.43%. Given GoodRx’s stronger consensus rating and higher probable upside, analysts clearly believe GoodRx is more favorable than Xylo Technologies.

Summary

GoodRx beats Xylo Technologies on 12 of the 13 factors compared between the two stocks.

About Xylo Technologies

Xylo Technologies Ltd, a technology-based company, provides medical-related devices and products in the United States, Europe, Asia, Israel, and internationally. The company operates through Corporate, E-commerce, Online Advertising & Internet Traffic Routing, Online Event Management, and Others segments. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it provides digital advertising platform; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops wireless vehicle battery charging technologies and modular electronic vehicles. The company was formerly known as Medigus Ltd. and changed its name to Xylo Technologies Ltd in April 2024. Xylo Technologies Ltd was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.

About GoodRx

GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscriptions, and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.